Clinical trial
BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic…
NCT00126646 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00126646 |
|---|---|
| Title | BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma |
| Official title | Phase I Study of BL22, A Recombinant Immunotoxin for Chronic Lymphocytic Leukemia and CD22+ Lymphomas |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Drug, Procedure |
| Interventions | BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy |
| Enrollment | 24 |
| Start date | Jun 1, 2005 |
| Primary completion | Mar 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Aug 4, 2005 |
| Last update posted | Jun 22, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: